Glenmark Pharmaceuticals reported a consolidated revenue of Rs. 34,338 Mn for Q2 FY 2024-25, growing by 7.1% YoY, with EBITDA of Rs. 6,019 Mn (up 30.2% YoY) and Profit After Tax of Rs. 3,545 Mn (PAT margin of 10.3%).
AI Assistant
Glenmark Pharmaceuticals Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.